Cancer Family
Sarcoma
CI-CAN-00000344SARExplore in graph →
634 active trials17 approved drugs182 evidence items
- NCIt
- C9118
- OncoTree
- SARCNOS
- DOID
- 1115
- MeSH
- D012509
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000344SARExplore in graph →
Clinical trials
2,687 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (365)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03725605 | LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04) | completed | Phase 2 | 6 | Lytix Biopharma ASINDUSTRY | 1 | Dec 5, 2025 | clinicaltrials |
| NCT02875548 | A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study(TRuST) | completed | Phase 1 / Phase 2 | 58 | Epizyme, Inc.INDUSTRY | 7 | Nov 4, 2025 |
| clinicaltrials |
| NCT03425279 | CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma | completed | Phase 1 / Phase 2 | 245 | BioAtla, Inc.INDUSTRY | 3 | Sep 23, 2025 | clinicaltrials |
| NCT04076579 | Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma | completed | Phase 2 | 29 | University of Michigan Rogel Cancer CenterOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT03899805 | A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas | completed | Phase 2 | 57 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT05080790 | Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma(DiTuSarc) | completed | Phase 2 | 7 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT05275426 | A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor | completed | Phase 2 | 14 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT01979393 | IRCI Gynae Sarcomas, High Grade Uterine Sarcoma | completed | Phase 2 | 58 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Aug 1, 2025 | clinicaltrials |
| NCT01027910 | PCI-24781 in Combination With Doxorubicin to Treat Sarcoma | completed | Phase 1 / Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | Jul 24, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT03951571 | Efficacy and Safety of Anlotinib in Adjuvant Therapy for High-grade Soft Tissue Sarcoma | completed | Phase 2 | 88 | Fudan UniversityOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT00742963 | Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 107 | ImmunoGenesisINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT05497843 | Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | completed | Phase 2 | 40 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03058289 | A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6(IT-01) | completed | Phase 1 / Phase 2 | 111 | Intensity Therapeutics, Inc.INDUSTRY | 2 | Feb 27, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02249949 | Efatutazone Dihydrochloride in Treating Patients With Previously Treated Myxoid Liposarcoma That Cannot Be Removed by Surgery | completed | Phase 2 | 15 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT05302921 | Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors | completed | Phase 2 | 5 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03809637 | A Study of Pemetrexed Plus Cisplatin in Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 37 | Yonsei UniversityOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT04963517 | Exercise Intervention for Bone Tumor Patients(proGAIT) | completed | Phase 2 / Phase 3 | 11 | Universität Duisburg-EssenOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT03838744 | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.(TOMAS2) | completed | Phase 2 | 130 | Italian Sarcoma GroupNETWORK | 1 | Dec 4, 2024 | clinicaltrials |
| NCT03148275 | Trametinib in Treating Patients With Epithelioid Hemangioendothelioma That is Metastatic, Locally Advanced, or Cannot Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03250325 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | completed | Phase 1 / Phase 2 | 8 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT04873375 | Cemiplimab for Secondary Angiosarcomas | completed | Phase 2 | 18 | Radboud University Medical CenterOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT04887298 | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | completed | Phase 1 / Phase 2 | 36 | Moleculin Biotech, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT06438614 | A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma(NICE) | completed | Phase 2 | 47 | Fundació Sant Joan de DéuOTHER | 1 | Aug 29, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT03338959 | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT02978859 | Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 29 | Columbia UniversityOTHER | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03320330 | Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 26 | Children's Oncology GroupNETWORK | 1 | Jul 15, 2024 | clinicaltrials |
| NCT02636725 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 33 | Jonathan Trent, MD, PhDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT02509598 | A Study of Lymphoseek® as a Lymphoid Tissue Targeting Agent in Pediatric Patients With Melanoma, Rhabdomyosarcoma, or Other Solid Tumors Who Are Undergoing Lymph Node Mapping | completed | Phase 2 | 24 | Cardinal Health 414, LLCINDUSTRY | 1 | Jun 28, 2024 | clinicaltrials |
| NCT02453191 | TVEC and Preop Radiation for Sarcoma (4 ml Dose) | completed | Phase 1 / Phase 2 | 30 | University of IowaOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT02029430 | A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma | completed | Phase 2 | 15 | ImmunityBio, Inc.INDUSTRY | 1 | Jun 11, 2024 | clinicaltrials |
| NCT05093322 | A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 13 | HutchmedINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT01514188 | Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma | completed | Phase 2 | 126 | ImmunityBio, Inc.INDUSTRY | 7 | May 29, 2024 | clinicaltrials |
| NCT02235701 | Study to Investigate the Safety and Activity of Aldoxorubicin Plus Ifosfamide/Mesna in Subjects With Metastatic Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 70 | ImmunityBio, Inc.INDUSTRY | 1 | May 29, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Dec 5, 2025source: clinicaltrials